Due to the growing burden of the cost of cancer care, stakeholders in medical oncology have discussed initiatives to control costs and drive quality. It is often suggested that the results of comparative effectiveness research (CER) can help all parties to make more informed healthcare decisions.
In this segment, panelists Peter Salgo, MD; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; Bryan Loy, MD; and Irwin W. Tischler, DO, discuss the use of CER in medical oncology. Drs Klein, Loy, and Tischler explain that CER has a great deal of potential; however, the United States has yet to use CER to its full potential for fear that it would be used to ration care, comments Dr Kolodziej. Variables that should be taken into account when utilizing CER include efficiency of care, total cost of care, and the concerns of consumers and patients, advises Dr Loy.
Considering CER in addition to the results of randomized controlled trials can be beneficial, notes Dr Tischler. Dr Klein adds that because clinical trials are conducted in controlled settings in highly selective patient populations, CER can provide information on effectiveness in “real-world” settings and patient populations.
Dr Kolodziej discusses the factors that concern stakeholders in regard to drug sequencing, and highlights the Green Park Consortium project, with which he is involved. Initiatives of the project include evaluating the sequencing of therapy in breast cancer and renal cell carcinoma, as many treatment options with overlapping mechanisms of action are available for these cancers.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More